Eileen Jill Muzzillo, MD
Internal Medicine · Fort Wayne, INNPI 1003343310
Payments from drug & device makers
Across 148 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$711
- AstraZeneca$332
- Amarin Pharma, Inc.$201
- Abbott$191
- Novo Nordisk$184
- AbbVie$159
- plus $1K from 18 others
What the payments were for
- Food & beverage$2,95899%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 33 | $711 |
| AstraZeneca | 18 | $332 |
| Amarin Pharma, Inc. | 11 | $201 |
| Abbott | 6 | $191 |
| Novo Nordisk | 10 | $184 |
| AbbVie | 10 | $159 |
| Boehringer Ingelheim | 8 | $143 |
| Sanofi-aventis U.S. LLC | 8 | $142 |
| Urovant Sciences Inc | 3 | $132 |
| Amgen | 2 | $117 |
| Pfizer | 5 | $82 |
| GSK | 5 | $79 |
| Nevro Corp. | 3 | $75 |
| Astellas Pharma US Inc | 5 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Esperion Therapeutics, Inc. | 3 | $59 |
| Novartis | 3 | $49 |
| Johnson & Johnson | 2 | $41 |
| Tactile Systems Technology Inc | 2 | $33 |
| Dexcom, Inc. | 2 | $29 |
| Xeris Pharmaceuticals, Inc. | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Exact Sciences | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,977 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 49 | $78,602 |
| JardianceEmpagliflozin | 64 | $72,413 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $42,556 |
| OzempicSemaglutide | 33 | $37,368 |
| EliquisApixaban | 23 | $33,363 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 20 | $23,431 |
| JanuviaSitagliptin Phosphate | 18 | $22,706 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $20,567 |
| XareltoRivaroxaban | 11 | $18,498 |
| Spiriva HandihalerTiotropium Bromide | 16 | $17,041 |
| RybelsusSemaglutide | 12 | $16,954 |
| GemtesaVibegron | 20 | $11,769 |
| Spiriva RespimatTiotropium Bromide | 15 | $11,077 |
| LinzessLinaclotide | 13 | $10,283 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $9,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $143 | $83,49079 claims |
| Lilly USA, LLCMounjaro | $711 | $78,60249 claims |
| Novo NordiskOzempic, Rybelsus | $184 | $54,32245 claims |
| GSKTrelegy Ellipta | $79 | $42,55634 claims |
| PfizerEliquis | $82 | $33,36323 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $142 | $23,43120 claims |
| Johnson & JohnsonXarelto | $41 | $18,49811 claims |
| AbbVieLinzess, Synthroid | $159 | $11,29035 claims |
| AstraZenecaSymbicort | $332 | $4,31013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Fort Wayne
- David IloFort Wayne$86K
- Anuradha KolliparaFort Wayne$30K
- Sumona KabirFort Wayne$28K
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.